A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
复制标题
DOI：
10.1016/j.leukres.2010.08.020
复制
发表时间：
2011-01-01
影响因子：
2.7
通讯作者：
Clark, Richard E.
中科院分区：
文献类型：
--
作者：
Estabragh, Zahra Raisi;Knight, Katy;Clark, Richard E.
体外研究表明，伊马替尼可能对心肌细胞有毒性。虽然回顾性研究没有显示临床心力衰竭，但这些研究并没有寻找细微的心脏损伤。我们对59例接受伊马替尼治疗的慢性髓性白血病（CML）患者进行了一项前瞻性心脏评估，使用超声心动图和MUGA扫描，中位时间为3.4年，后者在一年后再次进行。我们报告没有心肌恶化的证据，无论是在基线或超过12个月的伊马替尼治疗。伊马替尼心脏毒性不是CML患者或其顾问的重要临床考虑因素。(C) 2010 Elsevier Ltd.版权所有。
In vitro studies have suggested that imatinib may be toxic to cardiac myocytes. Though retrospective studies have not shown clinical heart failure, these did not look for subtle cardiac damage. We have carried out a prospective cardiac assessment in 59 chronic myeloid leukaemia (CML) patients treated with imatinib for a median of 3.4 years, using echocardiography and MUGA scanning, with the latter repeated after a further year. We report no evidence of myocardial deterioration, either at baseline or over 12 months of imatinib treatment. Imatinib cardiotoxicity is not an important clinical consideration for CML patients or their advisors. (C) 2010 Elsevier Ltd. All rights reserved.